ADMA BIOLOGICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
ADMA BIOLOGICS, INC. (ADMA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 1.68% for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-06.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2020-05-06
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2020-03-31 was 1.68%, a 36.12% decline year-over-year.
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2019-03-31 was 2.63%.
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2016-03-31 was 1.79%, a 5.79% decline year-over-year.
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2015-09-30 was 2.14%.
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2017 was 2.29%, a 27.93% increase from fiscal 2016.
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2016 was 1.79%, a 16.36% decline from fiscal 2015.
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2015 was 2.14%.
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2013 was 2.25%, a 38.89% increase from fiscal 2012.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2020-03-31 | 1.68% 10-Q · filed 2020-05-06 | |||
| 2019-09-30 | 2.92% 10-Q · filed 2019-11-06 | |||
| 2019-06-30 | 2.92% 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | 2.63% 10-Q · filed 2020-05-06 | |||
| 2018-09-30 | 2.97% 10-Q · filed 2019-11-06 | |||
| 2018-06-30 | 2.59% 10-Q · filed 2019-08-08 | |||
| 2017-12-31 | 2.29% 10-K · filed 2018-03-29 | |||
| 2017-09-30 | 2.29% 10-Q · filed 2018-11-09 | |||
| 2017-06-30 | 2.29% 10-Q · filed 2018-08-10 | |||
| 2016-12-31 | 1.79% 10-K · filed 2018-03-29 | |||
| 2016-09-30 | 1.79% 10-Q · filed 2017-11-03 | |||
| 2016-06-30 | 1.79% 10-Q · filed 2017-08-11 | |||
| 2016-03-31 | 1.79% 10-Q · filed 2017-05-12 | |||
| 2015-12-31 | 2.14% 10-K · filed 2017-02-24 | |||
| 2015-09-30 | 2.14% 10-Q · filed 2015-11-10 | 2.14% 10-Q · filed 2016-11-10 | ||
| 2015-06-30 | 1.90% 10-Q · filed 2016-08-12 | |||
| 2015-03-31 | 1.90% 10-Q · filed 2016-05-13 | |||
| 2014-03-31 | 2.25% 10-Q · filed 2015-05-12 | |||
| 2013-12-31 | 2.25% 10-K · filed 2015-03-09 | |||
| 2013-03-31 | 1.24% 10-Q · filed 2013-05-14 | |||
| 2012-12-31 | 1.62% 10-K · filed 2013-03-06 | |||
| 2012-09-30 | 1.62% 10-Q · filed 2012-11-13 | |||
| 2012-06-30 | 1.62% 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |